Robinson Elliott sold 0 shares of HNGE (indirect holdings)

Robinson Elliott sold 0 indirectly-held shares of Hinge Health, Inc. (HNGE) across 2 trades over 2026-09-02 to 2026-09-03.

Original reporting
SEC EDGAR · Robinson Elliott
Published Sep 4, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
high confidence
Mentioned
$HNGE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

No immediate market impact; serves as a compliance record.

02

Market read

Minimal relevance; routine disclosure with no change in holdings.

03

What to watch

Potential future transactions not disclosed in this filing.

Relevance 3/10Novelty 2/10Timing: filed Sep 4, 2026

Background

SEC Form 4 filing for Hinge Health, Inc. (HNGE) reporting a director's zero‑share sale.

Company-level read

Ticker impact

$HNGENeutralHigh confidence
Context

Form 4 shows director Robinson Elliott sold 0 shares, leaving no holdings.

Expected impact

none

Evidence & confidence

Zero-share sale does not affect supply‑demand dynamics.

Market effects

none

none

none

Counterpoint

Even a zero‑share filing could hint at upcoming insider activity.

Key entities

  • Robinson Elliott

    Director of Hinge Health who filed the Form 4.

  • Hinge Health, Inc.

    Digital health company providing musculoskeletal care.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.